Epilepsy - Pipeline Review, H2 2017

Date: August 16, 2017
Pages: 420
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E77FD94D4DCEN
Leaflet:

Download PDF Leaflet

Epilepsy - Pipeline Review, H2 2017
Epilepsy - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H2 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 13, 21, 2, 85, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 2 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Epilepsy - Overview
Epilepsy - Therapeutics Development
Epilepsy - Therapeutics Assessment
Epilepsy - Companies Involved in Therapeutics Development
Epilepsy - Drug Profiles
Epilepsy - Dormant Projects
Epilepsy - Discontinued Products
Epilepsy - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Epilepsy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Epilepsy - Pipeline by Adamas Pharmaceuticals Inc, H2 2017
Epilepsy - Pipeline by Advicenne SA, H2 2017
Epilepsy - Pipeline by Aequus Pharmaceuticals Inc, H2 2017
Epilepsy - Pipeline by Alexza Pharmaceuticals Inc, H2 2017
Epilepsy - Pipeline by Anavex Life Sciences Corp, H2 2017
Epilepsy - Pipeline by Aphios Corp, H2 2017
Epilepsy - Pipeline by Astellas Pharma Inc, H2 2017
Epilepsy - Pipeline by Aucta Pharmaceuticals LLC, H2 2017
Epilepsy - Pipeline by Bial - Portela & Ca SA, H2 2017
Epilepsy - Pipeline by BioCrea GmbH, H2 2017
Epilepsy - Pipeline by BioHealthonomics Inc, H2 2017
Epilepsy - Pipeline by Bionomics Ltd, H2 2017
Epilepsy - Pipeline by Biovista Inc, H2 2017
Epilepsy - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
Epilepsy - Pipeline by Catalyst Pharmaceuticals Inc, H2 2017
Epilepsy - Pipeline by Cerecor Inc, H2 2017
Epilepsy - Pipeline by Eisai Co Ltd, H2 2017
Epilepsy - Pipeline by Glialogix Inc, H2 2017
Epilepsy - Pipeline by Grifols SA, H2 2017
Epilepsy - Pipeline by GW Pharmaceuticals Plc, H2 2017
Epilepsy - Pipeline by Idorsia Ltd, H2 2017
Epilepsy - Pipeline by Insys Therapeutics Inc, H2 2017
Epilepsy - Pipeline by Iproteos SL, H2 2017
Epilepsy - Pipeline by Johnson & Johnson, H2 2017
Epilepsy - Pipeline by Knopp Biosciences LLC, H2 2017
Epilepsy - Pipeline by Lead Discovery Center GmbH, H2 2017
Epilepsy - Pipeline by Lipicard Technologies Ltd, H2 2017
Epilepsy - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017
Epilepsy - Pipeline by Marathon Pharmaceuticals LLC, H2 2017
Epilepsy - Pipeline by Marinus Pharmaceuticals Inc, H2 2017
Epilepsy - Pipeline by Medicure Inc, H2 2017
Epilepsy - Pipeline by Mitochon Pharmaceuticals Inc, H2 2017
Epilepsy - Pipeline by MMJ PhytoTech Ltd, H2 2017
Epilepsy - Pipeline by Monosol Rx LLC, H2 2017
Epilepsy - Pipeline by Neurocrine Biosciences Inc, H2 2017
Epilepsy - Pipeline by NeuroCycle Therapeutics GmbH, H2 2017
Epilepsy - Pipeline by Neuron Biopharma SA, H2 2017
Epilepsy - Pipeline by NoNO Inc, H2 2017
Epilepsy - Pipeline by Novartis AG, H2 2017
Epilepsy - Pipeline by OPKO Health Inc, H2 2017
Epilepsy - Pipeline by Ovid Therapeutics Inc, H2 2017
Epilepsy - Pipeline by Pfizer Inc, H2 2017
Epilepsy - Pipeline by Promius Pharma LLC, H2 2017
Epilepsy - Pipeline by Proximagen Ltd, H2 2017
Epilepsy - Pipeline by PTC Therapeutics Inc, H2 2017
Epilepsy - Pipeline by reMYND NV, H2 2017
Epilepsy - Pipeline by Retrophin Inc, H2 2017
Epilepsy - Pipeline by Sage Therapeutics Inc, H2 2017
Epilepsy - Pipeline by Saniona AB, H2 2017
Epilepsy - Pipeline by SciFluor Life Sciences LLC, H2 2017
Epilepsy - Pipeline by Serina Therapeutics Inc, H2 2017
Epilepsy - Pipeline by Shire Plc, H2 2017
Epilepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
Epilepsy - Pipeline by Suda Ltd, H2 2017
Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Epilepsy - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Epilepsy - Pipeline by Taro Pharmaceutical Industries Ltd, H2 2017
Epilepsy - Pipeline by The Cell-Factory BVBA, H2 2017
Epilepsy - Pipeline by Trillium Therapeutics Inc, H2 2017
Epilepsy - Pipeline by Turing Pharmaceuticals AG, H2 2017
Epilepsy - Pipeline by UCB SA, H2 2017
Epilepsy - Pipeline by Upsher-Smith Laboratories Inc, H2 2017
Epilepsy - Pipeline by VistaGen Therapeutics Inc, H2 2017
Epilepsy - Pipeline by Vitality Biopharma Inc, H2 2017
Epilepsy - Pipeline by Xenon Pharmaceuticals Inc, H2 2017
Epilepsy - Pipeline by XERIS Pharmaceuticals Inc, H2 2017
Epilepsy - Pipeline by Zogenix Inc, H2 2017
Epilepsy - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
Epilepsy - Dormant Projects, H2 2017
Epilepsy - Dormant Projects, H2 2017 (Contd.1), H2 2017
Epilepsy - Dormant Projects, H2 2017 (Contd.2), H2 2017
Epilepsy - Dormant Projects, H2 2017 (Contd.3), H2 2017
Epilepsy - Dormant Projects, H2 2017 (Contd.4), H2 2017
Epilepsy - Dormant Projects, H2 2017 (Contd.5), H2 2017
Epilepsy - Dormant Projects, H2 2017 (Contd.6), H2 2017
Epilepsy - Discontinued Products, H2 2017
Epilepsy - Discontinued Products, H2 2017 (Contd.1), H2 2017

LIST OF FIGURES

Number of Products under Development for Epilepsy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Adamas Pharmaceuticals Inc
Advicenne SA
Aequus Pharmaceuticals Inc
Alexza Pharmaceuticals Inc
Anavex Life Sciences Corp
Aphios Corp
Astellas Pharma Inc
Aucta Pharmaceuticals LLC
Bial - Portela & Ca SA
BioCrea GmbH
BioHealthonomics Inc
Bionomics Ltd
Biovista Inc
Biscayne Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
Cerecor Inc
Eisai Co Ltd
Glialogix Inc
Grifols SA
GW Pharmaceuticals Plc
Idorsia Ltd
Insys Therapeutics Inc
Iproteos SL
Johnson & Johnson
Knopp Biosciences LLC
Lead Discovery Center GmbH
Lipicard Technologies Ltd
Lotus Pharmaceutical Co Ltd
Marathon Pharmaceuticals LLC
Marinus Pharmaceuticals Inc
Medicure Inc
Mitochon Pharmaceuticals Inc
MMJ PhytoTech Ltd
Monosol Rx LLC
Neurocrine Biosciences Inc
NeuroCycle Therapeutics GmbH
Neuron Biopharma SA
NoNO Inc
Novartis AG
OPKO Health Inc
Ovid Therapeutics Inc
Pfizer Inc
Promius Pharma LLC
Proximagen Ltd
PTC Therapeutics Inc
reMYND NV
Retrophin Inc
Sage Therapeutics Inc
Saniona AB
SciFluor Life Sciences LLC
Serina Therapeutics Inc
Shire Plc
SK Biopharmaceuticals Co Ltd
Suda Ltd
Sumitomo Dainippon Pharma Co Ltd
Takeda Pharmaceutical Company Ltd
Taro Pharmaceutical Industries Ltd
The Cell-Factory BVBA
Trillium Therapeutics Inc
Turing Pharmaceuticals AG
UCB SA
Upsher-Smith Laboratories Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Xenon Pharmaceuticals Inc
XERIS Pharmaceuticals Inc
Zogenix Inc
Zynerba Pharmaceuticals Inc
Skip to top


Bionomics Ltd - Product Pipeline Review - 2016 US$ 1,275.00 Dec, 2016 · 47 pages

Ask Your Question

Epilepsy - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: